Increased hippocampal perfusion in early AD has been reported, but the underlying mechanism is still not clear. We hypothesized that epileptiform activity occurs in the hippocampus with AD and causes increased perfusion. Here, we designed a placebo-controlled study using an antiepileptic drug, Levetiracetam to modulate epileptic activity of the hippocampus. Nine subjects with AD were scanned following drug or placebo. We observed decreased perfusion and increased perfusion fluctuation in entorhinal cortex with Levetiracetam. These findings support the potential epileptic activity effects of entorhinal cortex in AD. Due to neighboring locations of hippocampus and entorhinal cortex, further work will probe the effects of potential misregistration.